Table 1.
Clinicopathological, morphological, and treatment characteristics for synchronously resected primary colorectal cancer and paired CRLM.
| Cohort n = 41 (%) | Median survival (mo) | Univariate HR (95% CI) | Multivariate HR (95% CI) | ||
|---|---|---|---|---|---|
| Age (<65) | <65 | 17 (41.5) | 45 | — | — |
| >65 | 24 (58.5) | 32 | 1.13 (0.55–2.32; P = 0.736) | — | |
| Gender | Male | 20 (48.8) | 30 | — | — |
| Female | 21 (51.2) | 43 | 0.91 (0.45–1.84; P = 0.786) | — | |
| ASA | I | 4 (9.8) | 38 | — | — |
| II | 27 (65.9) | 43 | 1.86 (0.43–7.94; P = 0.403) | — | |
| III | 10 (24.4) | 28 | 1.84 (0.39–8.69; P = 0.441) | — | |
| Site | Colon | 22 (53.7) | 32 | — | — |
| Rectum | 19 (46.3) | 43 | 0.91 (0.45–1.86; P = 0.806) | — | |
| T stage | T1/T2 | 3 (7.3) | 27 | — | — |
| T3/T4 | 38 (92.7) | 38 | 0.75 (0.18–3.17; P = 0.692) | — | |
| N Stage | N0 | 17 (41.5) | 62 | — | — |
| N1/N2 | 24 (58.5) | 25 | 2.54 (1.18–5.47; P = 0.017) | 2.57 (0.85–7.80; P = 0.095) | |
| Number of metastases | 1 | 24 (58.5) | 30 | — | — |
| 2–3 | 12 (29.3) | 37 | 1.00 (0.44–2.24; P = 0.991) | — | |
| >3 | 5 (12.2) | 47 | 1.20 (0.44–3.29; P = 0.718) | — | |
| Size of metastases (cm) | <5 | 36 (87.8) | 40 | — | — |
| >5 | 5 (12.2) | 27 | 2.05 (0.76–5.53; P = 0.155) | — | |
| R0 status (primary) | R0 | 29 (70.7) | 30 | — | — |
| R1/R2 | 12 (29.3) | 41 | 0.75 (0.34–1.64; P = 0.470) | — | |
| R0 status (metastasis) | R0 | 28 (68.3) | 46 | — | — |
| R1/R2 | 13 (31.7) | 24 | 1.94 (0.93–4.04; P = 0.076) | — | |
| Vascular Invasion (primary) | No | 8 (19.5) | 52 | — | — |
| Yes | 33 (80.5) | 34 | 1.13 (0.46–2.75; P = 0.793) | — | |
| Fong Score | Low (1/2) | 24 (58.5) | 44 | — | — |
| High (3/4) | 17 (41.5) | 24 | 2.25 (1.11–4.58; P = 0.025) | 1.16 (0.42–3.19; P = 0.778) | |
| Klintrup Makinen Grade (primary) | Low | 21 (51.2) | 27 | — | — |
| High | 20 (48.8) | 60 | 0.38 (0.17–0.86; P = 0.020) | — | |
| Klintrup Makinen Grade (metastasis) | Low | 23 (56.1) | 27 | — | — |
| High | 18 (43.9) | 57 | 0.40 (0.19–0.86; P = 0.020) | 0.36 (0.16–0.78; P = 0.010) | |
| TSP (primary) | Lowa | 18 (50.0) | 36 | — | — |
| High | 18 (50.0) | 41 | 1.05 (0.49–2.29; P = 0.892) | — | |
| TSP (metastasis) | Lowb | 18 (52.9) | 32 | — | — |
| High | 16 (47.1) | 44 | 1.27 (0.57–2.86; P = 0.559) | — | |
| Neoadjuvant treatment | No | 29 (70.7) | 27 | — | — |
| Yes | 12 (29.3) | 50 | 0.65 (0.29–1.46; P = 0.300) | — | |
| Adjuvant chemotherapy | No | 24 (58.5) | 38 | — | — |
| Yes | 17 (41.5) | 34 | 1.61 (0.78–3.33; P = 0.196) | — |
Note: Clinicopathological and treatment data for 41 patients managed by synchronous resection of primary colorectal cancer and CRLM are displayed. Univariate and multivariate survival analysis is presented and calculated using adjusted Cox proportional hazards regression model.
Abbreviations: ASA, American Society of Anesthesiologists Physical Status Classification; CI, confidence interval; HR, hazard ratio; TSP, tumor stromal percentage.
a36 primary colorectal cancer assessed for TSP.
b34 CRLM assessed for TSP.